PUNE, India, July 19, 2018 /PRNewswire/ --
According to a new market research report "Cell Counting Market by Product (Instruments (Spectrophotometer, Cell Counter, Hemocytometer, Flow Cytometer, Hematology Analyzer), Consumables (Reagent, Assay Kits, Microplate)), End User (Pharmaceutical, Hospital, Research) - Global Forecast to 2023", published by MarketsandMarkets™, the market is expected to reach USD 12.32 billion by 2023 from an estimated USD 8.84 billion in 2018, at a CAGR of 6.8%.
Browse 183 market data Tables and 49 Figures spread through 242 Pages and in-depth TOC on "Cell Counting Market"
Early buyers will receive 10% customization on this report
The major factors driving the growth of this market include the growing incidence of diseases and disorders, development of enhanced solutions and improved image analysis, and growing use of high-throughput flow cytometry and automated hematology analyzers.
By product, the consumables segment is expected to account for the largest share of the Cell Counting Market in 2018
On the basis of product, the consumables segment is expected to account for the largest share of the global Cell Counting Market in 2018. This large share can be attributed to the repeated consumption of consumables and accessories in various cell counting procedures. The growing focus on stem cell and cancer research is one of the major drivers for the growth of the cell counting consumables market along with the growing application of cell counting in quality control procedures in various industries, such as food and beverage, pharmaceutical, biotechnology products manufacturing, environmental monitoring, and water treatment.
By application, the research applications segment is estimated to hold the largest share in 2018
Based on application, the Cell Counting Market is segmented into research applications, clinical & diagnostic applications, and industrial applications. In 2018, the research applications segment is expected to account for the largest share of the Cell Counting Market. The large share of this segment can be attributed to the growing adoption of various cell counting instruments in research activities propelled by increasing research activities being undertaken for cancer, immunology, infectious diseases, HIV, drug discovery, and stem cells.
By end user, the research institutes segment is estimated to hold the largest share of the Cell Counting Market in 2018
On the basis of end user, the Cell Counting Market is segmented into research institutes, hospitals, clinical laboratories, pharmaceutical & biotechnology companies, and other end users (food and beverage companies and environmental testing companies). The research institutes segment is expected to account for the largest share in 2018. A surge in cell-based research and increasing research investment in the field of AIDS, cancer, infectious diseases, and blood disorders are some of the factors driving the growth of this market segment.
Ask for PDF Brochure @ https://www.marketsandmarkets.com/pdfdownload.asp?id=157450728
North America to dominate the market in 2018
North America is expected to account for the largest share of the Cell Counting Market in 2018, followed by Europe and Asia Pacific. The growing incidence rate of various infectious diseases, investment initiatives by the government, and presence of high-quality infrastructure for clinical and laboratory research are the major factors responsible for the large share of the North American Cell Counting Market. Moreover, a number of major global players are based in the US, owing to which, the US is a center for innovation in the Cell Counting Market.
The prominent players in the global Cell Counting Market are Danaher Corporation (US), Thermo Fisher Scientific (US), Becton, Dickinson and Company (US), Merck (Germany), Bio-Rad Laboratories (US), GE Healthcare (US), PerkinElmer (US), Agilent Technologies (US), BioTek Instruments (US), Tecan Group (Switzerland), Roche Diagnostics (Switzerland), Sysmex Corporation (Japan), HORIBA, Ltd. (Japan), Abbott Laboratories (US), and Siemens Healthineers (Germany).
Know more about the Cell Counting Market:
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact: Mr. Shelly Singh MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: email@example.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/cell-counting-market.asp
Connect with us on LinkedIn: http://www.linkedin.com/company/marketsandmarkets
Subscribe to our Free Newsletters!
Collagen plays a crucial role in glowing skin, strong nails and shiny hair. You can boost collagen ...
CRISPR technology is a simple but potent tool for editing any part of the genome (complete set of ...
FDA recently approved Mogamulizumab-kpkc, a human monoclonal antibody prescribed for adult ...View All